The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19
Brain, Behavior, & Immunity - Health · 2025-07 · 46 · 101015
DOI: 10.1016/j.bbih.2025.101015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, & Immunity - Health, 2025-07. Verfasst von Jiahui Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing An…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and hypothesis: Inflammation plays a crucial role in pathological mechanisms in schizophrenia (SZ) and the coronavirus disease 2019 (COVID-19), but the impact of dual inflammation on SZs' clinical outcomes is poorly understood. This study aimed to investigate whether dual inflammation impacts acute phase outcomes in patients with schizophrenia comorbid with COVID-19 (COVID-SZs). Study design: A total of 114 SZs and 49 COVID-SZs were recruited for this study. Plasma samples were collected and analyzed for levels of routine blood and inflammatory cytokines from all the participants. Then clinical symptoms, cognitive performance, and functional assessments were conducted at recruitment. One-way analysis of covariance examined the differences in inflammatory cytokines and correlation analyses examined the relationship between inflammatory cytokines and clinical outcomes. Study results: After controlling for age, gender, substance use status, and antipsychotic medications, levels of inflammatory cytokines increased in COVID-SZs groups compared to SZs groups. There were significantly higher total Positive and Negative Syndrome Scale (PANSS) scores and positive PANSS scores in COVID-SZs groups compared to SZs. As for cognitive performance, the COVID-SZs group had significantly worse performance in processing speed and attention than the SZs. The COVID-SZs group had significantly worse health status compared to the SZs. There were significantly different correlation patterns between the severity of psychiatric symptoms and inflammatory cytokines in COVID-SZs and SZs group. Conclusions: Findings indicate that dual inflammation exacerbates the acute phase clinical outcome of COVID-SZs. Suggesting a combined anti-inflammatory drug or the use of potentially anti-inflammatory antipsychotics in the acute phase of treatment to mitigate central nervous system damage. Regular monitoring of inflammatory marker levels can help reduce the risk of fluctuating psychiatric symptoms in patients with schizophrenia caused by inflammatory storms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Ho…
- Wuhan Mental Health Center, Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan, China.
- The Eighth Clinical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
- Department of Applied Psychology and Human Development, University of Toronto, Canada.
Förderung
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Natural Science Foundation of China
Zitieren
APA
Zhu, J., Shao, J., Wang, P., Liu, Y., Cheng, G., Zhou, Q., Li, Z., Li, J., Wang, M., Zhang, Z., Dong, X., & Shi, C. (2025). The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19. Brain, Behavior, & Immunity - Health, 46, 101015. https://doi.org/10.1016/j.bbih.2025.101015
Vancouver
Zhu J, Shao J, Wang P, Liu Y, Cheng G, Zhou Q, et al. The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19. Brain, Behavior, & Immunity - Health. 2025;46:101015. doi:10.1016/j.bbih.2025.101015
BibTeX
@article{Zhu2025,
author = {Zhu, Jiahui and Shao, Jiamin and Wang, Peng and Liu, Yuan and Cheng, Gangming and Zhou, Qi and Li, Zhuoran and Li, Jiayi and Wang, Mingqia and Zhang, Zhuokai and Dong, Xuan and Shi, Chuan},
title = {The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19},
journal = {Brain, Behavior, & Immunity - Health},
year = {2025},
volume = {46},
pages = {101015},
doi = {10.1016/j.bbih.2025.101015}
}
EUVIMED